- Home
- LU vs SLNO Comparison
LU vs SLNO Comparison
Compare LU & SLNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LU | SLNO |
|---|---|---|
| Founded | 2005 | 1999 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.3B |
| IPO Year | 2020 | 2014 |
Fundamental Metrics
Financial Performance| Metric | LU | SLNO |
|---|---|---|
| Price | $1.89 | $52.60 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $90.13 |
| AVG Volume (30 Days) | 1.5M | ★ 5.5M |
| Earning Date | 03-23-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 108.90 |
| EPS | N/A | ★ 0.39 |
| Revenue | N/A | ★ $1,450,788.00 |
| Revenue This Year | N/A | $151.77 |
| Revenue Next Year | $22.52 | $53.58 |
| P/E Ratio | ★ N/A | $134.60 |
| Revenue Growth | N/A | ★ 138.82 |
| 52 Week Low | $1.73 | $29.43 |
| 52 Week High | $4.57 | $89.12 |
Technical Indicators
Market Signals| Indicator | LU | SLNO |
|---|---|---|
| Relative Strength Index (RSI) | 36.85 | 77.64 |
| Support Level | $1.73 | $48.91 |
| Resistance Level | $2.77 | $55.47 |
| Average True Range (ATR) | 0.08 | 1.74 |
| MACD | 0.02 | 2.56 |
| Stochastic Oscillator | 40.51 | 99.51 |
Price Performance
Historical ComparisonAbout LU Lufax Holding Ltd each representing two (2)
Lufax Holding Ltd is a technology-empowered personal financial services platform in China. The company address the large unmet demand for personal lending among small business owners as well as salaried workers in China and provides tailor-made wealth management solutions to China's middle class and affluent population. Its platform has two hubs namely Retail Credit Facilitation Hub and Wealth Management Hub.
About SLNO Soleno Therapeutics Inc.
Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue.